Abstract

BACKGROUND
Hereditary angioedema (HAE) is a rare, autosomal dominant disorder caused by a C1-esterase inhibitor (C1-INH) deficiency (type 1) or qualitative defect (type 2). It is characterized by recurrent subcutaneous or submucosal edema attacks in various organs with a frequency from a few attacks to over one hundred attacks per year.
METHODS
We report on the treatment of 141 attacks in a patient with hereditary angioedema with the bradykinin B2 receptor antagonist icatibant.
RESULTS
During the entire observation period, efficacy of icatibant was maintained and not altered due to repeated administrations. No systemic or cardiovascular side affects were observed.
CONCLUSIONS
In the present case, icatibant proved to be an effective and safe drug for the symptomatic treatment of acute HAE attacks. Its efficacy was not impaired by repeated administrations over a three-year period in this patient.

Links

Publisher Full Text

Authors

Greve J, Hoffmann TK, Schuler P, Lang S, Chaker A, Bas M

Institution

Department of Otorhinolaryngology, University Hospital Essen, University Duisburg, Essen, Germany. jens.greve@uk-essen.de

Source

International journal of dermatology 50:10 2011 Oct pg 1294-5

MeSH

Anti-Inflammatory Agents, Non-Steroidal
Bradykinin
Clinical Trials, Phase III as Topic
Drug Administration Schedule
Hereditary Angioedema Types I and II
Humans
Long-Term Care
Male
Middle Aged
Receptor, Bradykinin B2
Treatment Outcome

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21950301